Drug
Nbi 98854
Nbi 98854: highest development phase Phase 3, developed by Neurocrine Biosciences. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-98854 NCT02274558 | Phase 3 | Tardive Dyskinesia |
| NBI-98854 NCT02581865 | Phase 2 | Tourette Syndrome |
| NBI-98854 NCT01688037 | Phase 2 | Tardive Dyskinesia |
| NBI-98854 NCT03732534 | Phase 2 | Tourette Syndrome |
| NBI-98854 NCT01267188 | Phase 2 | Tardive Dyskinesia |
Latest
No recent events.
Follow Nbi 98854 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.